Do CARs Need a Driver's License? Adoptive Cell Therapy with Chimeric Antigen Receptor-Redirected T Cells Has Caused Serious Adverse Events

Abstract

Human Gene TherapyVol. 21, No. 9 CommentaryDo CARs Need a Driver's License? Adoptive Cell Therapy with Chimeric Antigen Receptor-Redirected T Cells Has Caused Serious Adverse EventsHildegard Büning, Wolfgang Uckert, Klaus Cichutek, Robert E. Hawkins, and Hinrich AbkenHildegard BüningZentrum für Molekulare Medizin Köln and Klinik I für Innere Medizin, Uniklinik Köln, D-50937 Cologne, Germany.Search for more papers by this author, Wolfgang UckertMax-Delbrück-Centrum für Molekulare Medizin, D-13125 Berlin-Buch, Germany.Search for more papers by this author, Klaus CichutekPaul Ehrlich Institut, D-63225 Langen, Germany.Search for more papers by this author, Robert E. HawkinsDepartment of Medical Oncology, Paterson Institute of Cancer Research, University of Manchester, Manchester, M20 4BX, UK.Search for more papers by this author, and Hinrich AbkenZentrum für Molekulare Medizin Köln and Klinik I für Innere Medizin, Uniklinik Köln, D-50937 Cologne, Germany.Search for more papers by this authorPublished Online:30 Jul 2010https://doi.org/10.1089/hum.2010.131AboutSectionsView articleView Full TextPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited ByIn Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery1 February 2022 | ACS Biomaterials Science & Engineering, Vol. 8, No. 2Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering17 January 2020 | Nano Letters, Vol. 20, No. 3Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapySeminars in ImmunologyCurrent Perspectives in Cancer Immunotherapy30 September 2019 | Cancers, Vol. 11, No. 10Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models2 August 2017 | Frontiers in Immunology, Vol. 8Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2+ gastric cancer24 June 2016 | Cell Research, Vol. 26, No. 7Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity16 December 2015 | The Journal of Immunology, Vol. 196, No. 2Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor2 September 2015 | Oncotarget, Vol. 6, No. 30Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas22 January 2015 | OncoImmunology, Vol. 4, No. 3Dielectrophoresis-assisted 3D nanoelectroporation for non-viral cell transfection in adoptive immunotherapy1 January 2015 | Lab on a Chip, Vol. 15, No. 15Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma2 November 2014 | Cancer Immunology Research, Vol. 2, No. 11A closer look at chimeric antigen receptor specificityCytotherapy, Vol. 16, No. 10Engineered T cells for cancer treatmentCytotherapy, Vol. 16, No. 6Is cancer gene therapy an empty suit?The Lancet Oncology, Vol. 14, No. 11Cellular Immunotherapy for Carcinoma Using Genetically Modified EGFR-Specific T LymphocytesNeoplasia, Vol. 15, No. 5Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling17 April 2012 | Journal of Clinical Immunology, Vol. 32, No. 5A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells11 March 2012 | International Journal of Hematology, Vol. 95, No. 4Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses1 December 2011 | Cancer Immunology, Immunotherapy, Vol. 61, No. 1Cancer Immunotherapy Comes of AgeJournal of Clinical Oncology, Vol. 29, No. 36Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells David M. Barrett, Yangbing Zhao, Xiaojun Liu, Shuguang Jiang, Carmine Carpenito, Michael Kalos, Richard G. Carroll, Carl H. June, and Stephan A. Grupp12 August 2011 | Human Gene Therapy, Vol. 22, No. 12Transiently redirected T cells for adoptive transferCytotherapy, Vol. 13, No. 5Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirsCurrent Opinion in HIV and AIDS, Vol. 6, No. 1Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor14 November 2010 | Cancer Research, Vol. 70, No. 22Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?Hepatitis Research and Treatment, Vol. 2010 Volume 21Issue 9Sep 2010 InformationCopyright 2010, Mary Ann Liebert, Inc.To cite this article:Hildegard Büning, Wolfgang Uckert, Klaus Cichutek, Robert E. Hawkins, and Hinrich Abken.Do CARs Need a Driver's License? Adoptive Cell Therapy with Chimeric Antigen Receptor-Redirected T Cells Has Caused Serious Adverse Events.Human Gene Therapy.Sep 2010.1039-1042.http://doi.org/10.1089/hum.2010.131Online Ahead of Print:August 2, 2010Published in Volume: 21 Issue 9: July 30, 2010Online Ahead of Editing: July 14, 2010PDF download